-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
Read more: ASH25: Gallop’s LYT-200 shows unprecedented survival in AMLThe company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
More in Latest News
In Conversation With
-
SABCS25: Agendia’s genomic testing guides breast cancer care
Agendia’s VP of clinical development notes that new FLEX study data show genomic signatures predict chemotherapy benefit, improving personalized treatment for early breast cancer.
-
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company’s dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
-
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
-
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women’s health is critically underfunded and how a new initiative aims to change that.
-
mRNA technology set to revolutionize snakebite treatment
UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.
AI and Technology
Latest news
-
VUGENE partners with Inotiv to power AI-driven drug discovery
Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.
Expert Interviews
-
Beyond animal models: The new FDA human-first drug development framework
Dr Greg Tietjen, CEO of Revalia Bio, discusses the FDA’s push for human-first data and how it’s reshaping the entire drug development pipeline.
Sustainability In Pharma
Latest news
-
Building sustainable medical products: Polaroid exec on innovation and challenges
Head of Product at Polaroid Therapeutics, Paul Saunders, shares his approach to embedding sustainability in healthcare innovation.
Company Analysis
-
CVS Health makes headway in becoming environmentally sustainable
The progress and trend in the reduction of the GHG emissions and GHG emission intensity over the last six years reflect that CVS Health’s progress towards the goal of Net-zero by 2050 is on track.
Looking to read an in-depth analysis of Sustainability, AI, and the Latest Technology in healthcare sector
You can access members-only exclusive content for as little as $4.2 per month.
More Posts
-
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson’s treatment.
-
VUGENE partners with Inotiv to power AI-driven drug discovery
Lithuanian bioinformatics firm launches into pharmaceutical services via a strategic CRO collaboration aimed at accelerating multi-omics analysis.
-
HeartBeam’s stock shows strong pulse after FDA clearance
A cable-free, credit-card sized ECG device for at-home heart monitoring receives regulatory approval, paving the way for a 2026 launch.
-
Sanofi’s ASH 2025: Redefining rare blood disorder care
Sanofi’s head of rare diseases, Jeff Schaffnit, outlines the company’s dual approach: redefining hemophilia care and pioneering immune modulation for rare blood disorders.
-
Vyome’s stock rises on positive Phase II data for wound care drug
Vyome’s VT-1953 gel significantly reduced odor and pain in malignant fungating wounds, prompting plans for a pivotal Phase III study.
-
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
-
AVITA’s spray on skin cells slashes pain and hospital stays
Dr. Victoria Miles discusses how RECELL, which creates an autologous skin cell suspension, is reshaping burn care, access, and outcomes.
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
-
The $1 trillion blind spot: Bridging the gap in women’s health
Dr. Christian Tidona, founder and CEO of BioMed X, on why women’s health is critically underfunded and how a new initiative aims to change that.
-
Pharvaris stock rises following positive Phase III topline data
The company’s oral drug deucrictibant significantly sped up symptom relief in the Phase III trial, positioning it for 2026 regulatory filings.
-
Brainomix’s AI stroke tool doubles life-saving surgery rates in NHS study
The study indicated that Brainomix 360 Stroke led to a 100% increase in endovascular thrombectomy rates and sped up patient transfers across 107 UK hospitals.
-
mRNA technology set to revolutionize snakebite treatment
UK researcher Prof. Vaiyapuri discusses how Covid vaccine technology could soon neutralize deadly snake venom, preventing death and disability for millions.
-
Regeneron and Tessera ink $275 mil pact for gene editing therapy
The companies will co-develop TSRA-196, a potential one-time genetic treatment for alpha-1 antitrypsin deficiency.
-
Santersus secures funding to advance blood purification tech
Swiss biotech raises Series A financing to drive pivotal trials for its blood purification technology for sepsis and lupus therapy.
-
Saliva pregnancy test hits Australian shelves
Salignostics partners with Coles Supply to launch its innovative SaliStick saliva-based pregnancy test across Australia.